Foundayo Shows Significant Weight Loss in Menopausal Women
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 49 minutes ago
0mins
Source: Newsfilter
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo lost up to 28.0 lbs (12.8%), 30.4 lbs (14.4%), and 28.2 lbs (14.1%) respectively over 72 weeks, demonstrating significant weight loss effects that could reshape weight management strategies for women.
- Diabetic Patient Performance: In the ATTAIN-2 trial, despite having type 2 diabetes, pre-menopausal, peri-menopausal, and post-menopausal women lost up to 23.4 lbs (11.3%), 18.5 lbs (8.9%), and 27.8 lbs (13.6%), indicating Foundayo's efficacy in complex conditions and potentially broadening its market applications.
- Waist Circumference Reduction: Participants in both trials experienced waist circumference reductions of up to 4.9 inches (12.5 cm) and 4.3 inches (11.0 cm), which not only aids in reducing abdominal fat but may also lower cardiometabolic risks, enhancing women's health outcomes.
- Market Potential: With increasing demand for weight loss medications among menopausal women, Foundayo's success could present new growth opportunities for Eli Lilly in the obesity treatment market, particularly in strategic positioning within women's health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1125.270
Low
950.00
Averages
1192
High
1500
Current: 1125.270
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo achieved significant weight loss of up to 30.4 lbs (14.4%) over 72 weeks across all stages of menopause, demonstrating the drug's efficacy in weight management.
- Diabetic Patient Outcomes: Even among women with type 2 diabetes, those in ATTAIN-2 experienced significant weight loss, with reductions up to 27.8 lbs (13.6%), indicating Foundayo's effectiveness across varying health conditions.
- Waist Circumference Reduction: Participants in both trials saw meaningful reductions in waist circumference, with decreases of up to 4.9 inches (12.5 cm) in ATTAIN-1 and 4.3 inches (11.0 cm) in ATTAIN-2, correlating with reduced abdominal fat and cardiometabolic risk.
- Market Potential: These findings underscore Foundayo's significance in weight management for women, particularly during the often-overlooked menopausal phase, potentially providing Lilly with robust support for further expansion in the obesity treatment market.
See More
Eli Lilly Reports Positive Phase 3 Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg of retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, indicating the drug's potential to transform obesity treatment and market dynamics.
- Improvement in Related Conditions: Retatrutide not only facilitated weight loss but also reduced knee osteoarthritis pain by 4.3 points (73.1%) and the severity of moderate-to-severe obstructive sleep apnea by 36.1 events/hour (60.6%), demonstrating its efficacy across multiple obesity-related conditions.
- Diabetes Management Breakthrough: In the TRANSCEND-T2D-1 trial, retatrutide achieved A1C reductions of up to 2.0% and an average weight loss of 36.6 lbs (16.8%) at 40 weeks, highlighting its significant role in diabetes management and potential market impact.
- Cardiovascular Risk Reduction: In TRIUMPH-1, retatrutide significantly lowered triglycerides by 41%, non-HDL cholesterol by 24.2%, and systolic blood pressure by 12.3 mmHg, suggesting its potential to improve cardiovascular health and broaden market opportunities for the company.
See More
Eli Lilly's Foundayo Shows Significant Weight Loss in Women
- Clinical Trial Results: Post-hoc analyses from the ATTAIN-1 and ATTAIN-2 trials involving over 1,500 female participants reveal that those taking the highest dose of Foundayo achieved significant weight loss at all stages of menopause, with perimenopausal women losing up to 30.4 lbs (14.4%) and postmenopausal women losing 28.2 lbs (14.1%), highlighting the drug's effectiveness in weight management.
- Impact on Diabetic Patients: In the ATTAIN-2 study, women with type 2 diabetes also experienced significant weight loss across all menopause stages while taking Foundayo, demonstrating the drug's unique advantages in addressing weight loss challenges for this specific population, potentially offering new treatment options.
- Waist Circumference Reduction: Participants in both studies noted meaningful reductions in waist circumference, an important measure linked to decreased abdominal fat and lower cardiometabolic risk, further underscoring Foundayo's potential in improving women's metabolic health.
- FDA Approval and Multiple Indications: Foundayo (orforglipron) is FDA-approved for adults with obesity or weight-related medical issues, and in addition to chronic weight management, it is being studied for potential treatment of type 2 diabetes, obstructive sleep apnea, and other conditions, showcasing its broad clinical application prospects.
See More
Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo lost 28.0 lbs (12.8%), 30.4 lbs (14.4%), and 28.2 lbs (14.1%) respectively over 72 weeks, demonstrating the drug's effectiveness in weight reduction.
- Diabetic Patient Outcomes: In ATTAIN-2, despite having type 2 diabetes, pre-menopausal, peri-menopausal, and post-menopausal women lost 23.4 lbs (11.3%), 18.5 lbs (8.9%), and 27.8 lbs (13.6%), indicating Foundayo's potential in complex health conditions.
- Waist Circumference Reduction: Participants in both trials experienced waist circumference reductions of 4.9 inches (12.5 cm) and 4.3 inches (11.0 cm), which not only aids in reducing abdominal fat but also significantly lowers cardiometabolic risks.
- Market Implications: As demand for weight loss medications among menopausal women rises, the successful trial results of Foundayo may enhance its market acceptance, further solidifying Eli Lilly's leadership in obesity treatment.
See More
Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo lost up to 28.0 lbs (12.8%), 30.4 lbs (14.4%), and 28.2 lbs (14.1%) respectively over 72 weeks, demonstrating significant weight loss effects that could reshape weight management strategies for women.
- Diabetic Patient Performance: In the ATTAIN-2 trial, despite having type 2 diabetes, pre-menopausal, peri-menopausal, and post-menopausal women lost up to 23.4 lbs (11.3%), 18.5 lbs (8.9%), and 27.8 lbs (13.6%), indicating Foundayo's efficacy in complex conditions and potentially broadening its market applications.
- Waist Circumference Reduction: Participants in both trials experienced waist circumference reductions of up to 4.9 inches (12.5 cm) and 4.3 inches (11.0 cm), which not only aids in reducing abdominal fat but may also lower cardiometabolic risks, enhancing women's health outcomes.
- Market Potential: With increasing demand for weight loss medications among menopausal women, Foundayo's success could present new growth opportunities for Eli Lilly in the obesity treatment market, particularly in strategic positioning within women's health.
See More
Employers Cut Coverage for Weight-Loss Drugs Amid Rising Costs
- Coverage Reduction: According to The Wall Street Journal, employers like Cigna and PricewaterhouseCoopers are increasingly limiting or eliminating coverage for GLP-1 drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, reflecting growing concerns over rising healthcare costs.
- Employer Responses: New data reveals that 11% of large employers have either dropped or plan to drop coverage for GLP-1 medications, while over a quarter are tightening utilization controls, indicating heightened awareness of the financial implications of these drugs.
- Market Challenges: Despite strong demand for GLP-1 drugs, decisions by employers and insurers regarding coverage will significantly impact the future growth trajectory of the multibillion-dollar obesity drug market, particularly in balancing healthcare costs with employee benefits.
- Long-Term Cost Benefits: Some companies continue to advocate for broader coverage, arguing that GLP-1 medications may lower long-term healthcare costs by reducing obesity-related illnesses and hospitalizations, yet commercial insurance coverage for weight-loss use remains stagnant at around 50%.
See More
Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo achieved significant weight loss of up to 30.4 lbs (14.4%) over 72 weeks across all stages of menopause, demonstrating the drug's efficacy in weight management.
- Diabetic Patient Outcomes: Even among women with type 2 diabetes, those in ATTAIN-2 experienced significant weight loss, with reductions up to 27.8 lbs (13.6%), indicating Foundayo's effectiveness across varying health conditions.
- Waist Circumference Reduction: Participants in both trials saw meaningful reductions in waist circumference, with decreases of up to 4.9 inches (12.5 cm) in ATTAIN-1 and 4.3 inches (11.0 cm) in ATTAIN-2, correlating with reduced abdominal fat and cardiometabolic risk.
- Market Potential: These findings underscore Foundayo's significance in weight management for women, particularly during the often-overlooked menopausal phase, potentially providing Lilly with robust support for further expansion in the obesity treatment market.
See More
Eli Lilly Reports Positive Phase 3 Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg of retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, indicating the drug's potential to transform obesity treatment and market dynamics.
- Improvement in Related Conditions: Retatrutide not only facilitated weight loss but also reduced knee osteoarthritis pain by 4.3 points (73.1%) and the severity of moderate-to-severe obstructive sleep apnea by 36.1 events/hour (60.6%), demonstrating its efficacy across multiple obesity-related conditions.
- Diabetes Management Breakthrough: In the TRANSCEND-T2D-1 trial, retatrutide achieved A1C reductions of up to 2.0% and an average weight loss of 36.6 lbs (16.8%) at 40 weeks, highlighting its significant role in diabetes management and potential market impact.
- Cardiovascular Risk Reduction: In TRIUMPH-1, retatrutide significantly lowered triglycerides by 41%, non-HDL cholesterol by 24.2%, and systolic blood pressure by 12.3 mmHg, suggesting its potential to improve cardiovascular health and broaden market opportunities for the company.
See More
Eli Lilly's Foundayo Shows Significant Weight Loss in Women
- Clinical Trial Results: Post-hoc analyses from the ATTAIN-1 and ATTAIN-2 trials involving over 1,500 female participants reveal that those taking the highest dose of Foundayo achieved significant weight loss at all stages of menopause, with perimenopausal women losing up to 30.4 lbs (14.4%) and postmenopausal women losing 28.2 lbs (14.1%), highlighting the drug's effectiveness in weight management.
- Impact on Diabetic Patients: In the ATTAIN-2 study, women with type 2 diabetes also experienced significant weight loss across all menopause stages while taking Foundayo, demonstrating the drug's unique advantages in addressing weight loss challenges for this specific population, potentially offering new treatment options.
- Waist Circumference Reduction: Participants in both studies noted meaningful reductions in waist circumference, an important measure linked to decreased abdominal fat and lower cardiometabolic risk, further underscoring Foundayo's potential in improving women's metabolic health.
- FDA Approval and Multiple Indications: Foundayo (orforglipron) is FDA-approved for adults with obesity or weight-related medical issues, and in addition to chronic weight management, it is being studied for potential treatment of type 2 diabetes, obstructive sleep apnea, and other conditions, showcasing its broad clinical application prospects.
See More
Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo lost 28.0 lbs (12.8%), 30.4 lbs (14.4%), and 28.2 lbs (14.1%) respectively over 72 weeks, demonstrating the drug's effectiveness in weight reduction.
- Diabetic Patient Outcomes: In ATTAIN-2, despite having type 2 diabetes, pre-menopausal, peri-menopausal, and post-menopausal women lost 23.4 lbs (11.3%), 18.5 lbs (8.9%), and 27.8 lbs (13.6%), indicating Foundayo's potential in complex health conditions.
- Waist Circumference Reduction: Participants in both trials experienced waist circumference reductions of 4.9 inches (12.5 cm) and 4.3 inches (11.0 cm), which not only aids in reducing abdominal fat but also significantly lowers cardiometabolic risks.
- Market Implications: As demand for weight loss medications among menopausal women rises, the successful trial results of Foundayo may enhance its market acceptance, further solidifying Eli Lilly's leadership in obesity treatment.
See More
Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo lost up to 28.0 lbs (12.8%), 30.4 lbs (14.4%), and 28.2 lbs (14.1%) respectively over 72 weeks, demonstrating significant weight loss effects that could reshape weight management strategies for women.
- Diabetic Patient Performance: In the ATTAIN-2 trial, despite having type 2 diabetes, pre-menopausal, peri-menopausal, and post-menopausal women lost up to 23.4 lbs (11.3%), 18.5 lbs (8.9%), and 27.8 lbs (13.6%), indicating Foundayo's efficacy in complex conditions and potentially broadening its market applications.
- Waist Circumference Reduction: Participants in both trials experienced waist circumference reductions of up to 4.9 inches (12.5 cm) and 4.3 inches (11.0 cm), which not only aids in reducing abdominal fat but may also lower cardiometabolic risks, enhancing women's health outcomes.
- Market Potential: With increasing demand for weight loss medications among menopausal women, Foundayo's success could present new growth opportunities for Eli Lilly in the obesity treatment market, particularly in strategic positioning within women's health.
See More
Employers Cut Coverage for Weight-Loss Drugs Amid Rising Costs
- Coverage Reduction: According to The Wall Street Journal, employers like Cigna and PricewaterhouseCoopers are increasingly limiting or eliminating coverage for GLP-1 drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, reflecting growing concerns over rising healthcare costs.
- Employer Responses: New data reveals that 11% of large employers have either dropped or plan to drop coverage for GLP-1 medications, while over a quarter are tightening utilization controls, indicating heightened awareness of the financial implications of these drugs.
- Market Challenges: Despite strong demand for GLP-1 drugs, decisions by employers and insurers regarding coverage will significantly impact the future growth trajectory of the multibillion-dollar obesity drug market, particularly in balancing healthcare costs with employee benefits.
- Long-Term Cost Benefits: Some companies continue to advocate for broader coverage, arguing that GLP-1 medications may lower long-term healthcare costs by reducing obesity-related illnesses and hospitalizations, yet commercial insurance coverage for weight-loss use remains stagnant at around 50%.
See More
